Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298022 · ClinicalTrials.gov registry record · Phase 2
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
A Phase 2 study, sponsored by AltruBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03298022 is a Phase 2 study that was terminated before completion, run by AltruBio. The registered enrollment target is 24 participants.
The verdict
NCT03298022, a Phase 2 study, was terminated before completion, sponsored by AltruBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or anti-integrin treatments.
Interventions
- BIOLOGICAL ALTB-168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03298022
The ClinicalTrials.gov registry entry for NCT03298022 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AltruBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALTB-168 is the first listed.
NCT03298022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03298022 about?
NCT03298022 is a clinical study titled "Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC". To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or anti-integrin treatments.
What is the current status of trial NCT03298022?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-05-04. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03298022?
The interventions under investigation include: ALTB-168 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03298022?
This trial is sponsored by AltruBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.